Loading
A phase 2 trial of Olaparib in advanced solid tumours, run by Merck Sharp & Dohme LLC, active and no longer recruiting.
Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002) is a phase 2 interventional study registered as NCT03742895 by Merck Sharp & Dohme LLC, with 329 participants enrolled, started 2018-12-12 and due to reach its primary completion in 2025-08-12. Interventions recorded: Olaparib. Results have been posted on the registry.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
329 enrolled.
95% CI 9.2 to 25.8; Figures from the ClinicalTrials.gov results section (first posted 2026-08-14), not from a publication · 95% CI 3.9 to 16.8 · 95% CI 4.5 to 14.5 · 95% CI 3.7 to 71.0
Source| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Cohorts 1, 2, 3: Objective Response Rate (ORR) as Assessed by Blinded Independent Central Review (BICR) Per Modified Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) or Prostate Cancer Working Group (PCWG)-Modified RECIST 1.1primary | Cohort 1: BRCA1/2 Mutated | 86 | 16.3% | - | - | link |
| Cohort 2: HRD+, HRR Non-mutated | 90 | 8.9% | ||||
| Cohort 2: HRRm, BRCA1/2 Non-mutated | 140 | 8.6% | ||||
| Cohort 3: sBRCAm Breast Cancer | 7 | 28.6% |
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares PARP inhibitors, Olaparib, AstraZeneca, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares PARP inhibitors, Olaparib, Merck & Co. (MSD), AstraZeneca and the tag pipeline.
Shares PARP inhibitors, Olaparib, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Merck & Co. (MSD), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares PARP inhibitors, Olaparib, AstraZeneca and the tag pipeline.
Shares Merck & Co. (MSD), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Merck & Co. (MSD), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Merck & Co. (MSD), Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/